{"id":525521,"date":"2024-07-26T00:00:00","date_gmt":"2024-07-26T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/nrlfim0005-2024-biopharma-graft-versus-host-disease-landscape-forecast-niche-rare-disease-landscape-forecast-us-eu5\/"},"modified":"2026-03-31T10:29:08","modified_gmt":"2026-03-31T10:29:08","slug":"nrlfim0005-2024-biopharma-graft-versus-host-disease-landscape-forecast-niche-rare-disease-landscape-forecast-us-eu5","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/nrlfim0005-2024-biopharma-graft-versus-host-disease-landscape-forecast-niche-rare-disease-landscape-forecast-us-eu5\/","title":{"rendered":"Graft Versus Host Disease &#8211; Landscape &#038; Forecast &#8211; Niche &#038; Rare Disease Landscape &#038; Forecast (US\/EU5)"},"content":{"rendered":"<p>Graft versus host disease (<abbr data-abbreviation-entity=\"6247\" title=\"graft versus host disease\">GVHD<\/abbr>) is a potentially life-threatening complication of allogenic hematopoietic stem cell transplantation (<abbr data-abbreviation-entity=\"5116\" title=\"hematopoietic stem-cell transplantation\">HSCT<\/abbr>). Steroids have been the first-line therapy for the prevention and treatment of <abbr data-abbreviation-entity=\"6247\" title=\"graft versus host disease\">GVHD<\/abbr> for decades, and since 2019, three therapies have been approved for steroid-refractory <abbr data-abbreviation-entity=\"6247\" title=\"graft versus host disease\">GVHD<\/abbr>: Jakafi \/ Jakavi (ruxolitinib), Imbruvica (ibrutinib), and Rezurock (belumosudil). Despite these options, there is a substantial need for more-effective therapies for steroid-refractory disease, as well as better first-line and prophylactic treatments for <abbr data-abbreviation-entity=\"6247\" title=\"graft versus host disease\">GVHD<\/abbr>. In this content, we explore the clinical and commercial potential of key current and emerging therapies for <abbr data-abbreviation-entity=\"6247\" title=\"graft versus host disease\">GVHD<\/abbr>.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How large is the <abbr data-abbreviation-entity=\"6247\" title=\"graft versus host disease\">GVHD<\/abbr> population, and how will it change through 2033? What percentage of the <abbr data-abbreviation-entity=\"6247\" title=\"graft versus host disease\">GVHD<\/abbr> population receive drug treatment?<\/li>\n<li>What is the current treatment landscape and medical practice in <abbr data-abbreviation-entity=\"6247\" title=\"graft versus host disease\">GVHD<\/abbr>, and what are the greatest unmet needs according to experts?<\/li>\n<li>Which pipeline products are the most promising, and what sales\/uptake could they secure in <abbr data-abbreviation-entity=\"6247\" title=\"graft versus host disease\">GVHD<\/abbr>? Which therapies of note are progressing in earlier phases?<\/li>\n<li>What are the drivers and constraints in the <abbr data-abbreviation-entity=\"6247\" title=\"graft versus host disease\">GVHD<\/abbr> market, and how will the market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>Content highlights<\/strong><\/p>\n<p><strong>Geography:<\/strong> United States and <abbr data-abbreviation-entity=\"6092\" title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr><\/p>\n<p><strong>Primary research: <\/strong>Six country-specific interviews with thought-leading <abbr data-abbreviation-entity=\"6247\" title=\"graft versus host disease\">GVHD<\/abbr> specialists. Supported by survey data collected for this study<\/p>\n<p><strong>Epidemiology: <\/strong>Diagnosed incident cases of acute and chronic <abbr data-abbreviation-entity=\"6247\" title=\"graft versus host disease\">GVHD<\/abbr>, diagnosed incident cases of acute <abbr data-abbreviation-entity=\"6247\" title=\"graft versus host disease\">GVHD<\/abbr> by grade, drug-treated cases of <abbr data-abbreviation-entity=\"6247\" title=\"graft versus host disease\">GVHD<\/abbr> by country<\/p>\n<p><strong>Forecast: <\/strong>Drug-level sales and patient share of key <abbr data-abbreviation-entity=\"6247\" title=\"graft versus host disease\">GVHD<\/abbr> therapies through 2033<\/p>\n<p><strong>Drug treatments: <\/strong>Coverage of key current and emerging therapies<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Niche &#038; Rare Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Key feature<\/strong><\/p>\n<p>Niche &#038; Rare Disease Landscape &#038; Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n","protected":false},"template":"","class_list":["post-525521","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-graft-versus-host-disease","biopharma-therapy-areas-transplant","biopharma-geography-us","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/525521","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/525521\/revisions"}],"predecessor-version":[{"id":575933,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/525521\/revisions\/575933"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=525521"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}